Con­gres­sion­al reps push FDA to adopt ‘clear, con­spic­u­ous and neu­tral’ rule for phar­ma drug ads

A hand­ful of House rep­re­sen­ta­tives — in­clud­ing phar­ma hear­ing fre­quent in­ter­roga­tor Katie Porter — want to com­pel the FDA to fi­nal­ly adopt a 2010 pro­pos­al about dis­trac­tions in di­rect-to-con­sumer drug ads. The long-on-the-shelf pro­pos­al would de­vel­op stan­dards to make phar­ma drug risks and side ef­fects ap­pear “in a clear, con­spic­u­ous, and neu­tral man­ner.”

Rep. Abi­gail Span­berg­er (D-VA) is lead­ing the House charge on the “Ban­ning Mis­lead­ing Drugs Act,” joined by Reps. Porter (D-CA), Su­san Wild (D-PA), Cindy Axne (D-IA) and Ang­ie Craig (D-MN), in push­ing the FDA to fi­nal­ly act. The pro­posed rule specif­i­cal­ly tar­gets the “ma­jor state­ment” in TV and ra­dio drug ads.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER